Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164422 · ClinicalTrials.gov registry record · Phase 2
Does Guanfacine Attenuate Stress-Induced Drinking?
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02164422: Completed Phase 2 study, sponsored by Yale University.
NCT02164422 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02164422, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the amount of alcohol consumption (mls consumed) during the 2-hour self-administration period across two laboratory sessions.
Primary Outcome
mL per 15 minutes during 2-hour ad-lib drinking period
Interventions
- DRUG Placebo
- DRUG Guanfacine 3mg/day
- DRUG Guanfacine 1.5mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-06 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
What the finished NCT02164422 record still lists
NCT02164422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02164422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02164422 about?
NCT02164422 is a clinical study titled "Does Guanfacine Attenuate Stress-Induced Drinking?". Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the amount of alcohol consumption (mls consumed) during the 2-hour self-administration period across two laboratory sessions.
What is the current status of trial NCT02164422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-06. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02164422?
The interventions under investigation include: Placebo (DRUG), Guanfacine 3mg/day (DRUG), Guanfacine 1.5mg/day (DRUG).
Who is sponsoring clinical trial NCT02164422?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02164422's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia